Drug Type Biosimilar, Monoclonal antibody |
Synonyms Olinvacimab Biosimilar (Wincal Biopharm Inc.), 奥伐西单抗生物类似药(Wincal Biopharm Inc.) |
Target |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Preclinical | US | 28 Jun 2024 | |
Diabetic macular oedema | Preclinical | US | 28 Jun 2024 |